- Accueil
- Le département
- Notre équipe
- Dr Tu Nguyen-Ngoc
Dr Tu Nguyen-Ngoc
Spécialisations
- Cancers du thorax
- Immuno-oncologie
- Études cliniques (Phase I et II)
Domaines d'intérêt académique et/ou clinique
Cancers du thorax, immuno-oncologie, cancers urologiques, sarcomes, mélanomes, recherche translationnelle
Publications scientifiques sélectionnées
Neoantigen-Specific CD8 T-Cells with High Structural Avidity Preferentially Reside and Eliminate Tumors.
Harari A, Schmidt J, Chiffelle J, Perez MAS, Magnin M, Bobisse S, Arnaud M, Genolet R, Cesbron J, Barras D, Navarro Rodrigo B, Benedetti F, Michel A, Queiroz L, Baumgaertner P, GuillaumeP, Hebeisen M, Michielin O, Nguyen-Ngoc T, Huber F, Irving M, Tissot
Nat commun 2023 (accepted)
[Prostate cancer in the era of precision medicine: a new horizon].
Nguyen-Ngoc T, Berthold D, Normand C
Rev Med Suisse. 2023 May 17;19(827):950-956
[Oncology: what's new in 2022].
Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Di
Rev Med Suisse. 2023 Jan 18;19(N° 809-10):52-57
Salvage LATTICE radiotherapy for a growing tumour despite conventional radio chemotherapy treatment of lung cancer.
Kinj R, Casutt A, Nguyen-Ngoc T, Mampuya A, Schiappacasse L, Bourhis J, Huck C, Patin D, Marguet M, Zeverino M, Moeckli R, Gonzalez M, Lovis A, Ozsahin M
Clin Transl Radiat Oncol. 2023 Mar;39:100557
[Targeted therapies and non-small cell carcinomas : novelties].
Stauber R, Gro S L, Nguyen-Ngoc T, Mederos N, Bouchaab H, Peters S, Abdelhamid K
Rev Med Suisse. 2022 May 18;18(782):970-975
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
Arnaud M, Chiffelle J, Genolet R, Navarro Rodrigo B, Perez MAS, Huber F, Magnin M, Nguyen-Ngoc T, Guillaume P, Baumgaertner P, Chong C, Stevenson BJ, Gfeller D, Irving M, Speiser DE, Schmidt J, Zoete V, Kandalaft LE, Bassani-Sternberg M, Bobisse S, Coukos
Nat Biotechnol. 2022 May;40(5):656-660
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M
J Thorac Oncol. 2021 Feb;16(2):318-326
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Jerby-Arnon L, Neftel C, Shore ME, Weisman HR, Mathewson ND, McBride MJ, Haas B, Izar B, Volorio A, Boulay G, Cironi L, Richman AR, Broye LC, Gurski JM, Luo CC, Mylvaganam R, Nguyen L, Mei S, Melms JC, Georgescu C, Cohen O, Buendia-Buendia JE, Segerstolpe
Nat Med. 2021 Feb;27(2):289-300
The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies.
Boulay G, Cironi L, Garcia SP, Rengarajan S, Xing YH, Lee L, Awad ME, Naigles B, Iyer S, Broye LC, Keskin T, Cauderay A, Fusco C, Letovanec I, Chebib I, Nielsen PG, Tercier S, Cherix S, Nguyen-Ngoc T, Cote G, Choy E, Provero P, Suvà ML, Rivera MN, Stamenk
Life Sci Alliance. 2021 Feb;4(2)
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Gannon PO, Harari A, Auger A, Murgues C, Zangiacomi V, Rubin O, Ellefsen Lavoie K, Guillemot L, Navarro Rodrigo B, Nguyen-Ngoc T, Rusakiewicz S, Rossier L, Boudousquié C, Baumgaertner P, Zimmermann S, Trueb L, Iancu EM, Sempoux C, Demartines N, Coukos G,
Cytotherapy. 2020 Dec;22(12):780-791
[Small-cell lung cancer: management and novelties].
Abdelhamid K, Kakourou A, Degrauwe N, Nikolopoulou A, Bouchaab H, Peters S, Nguyen-Ngoc T, Mederos N
Rev Med Suisse. 2020 May 27;16(695):1079-1085
[Surgical treatment of proximal femur metastases].
Mustaki L, Gallusser N, Steinmetz S, Aebischer O, Maeder B, Morattel B, Zyska Cherix A, Nguyen-Ngoc T, Moerenhout K, Cherix S
Rev Med Suisse. 2019 Dec 11;15(675):2288-2292
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, Wang H, Ercolano G, Ahmed R, Lozano LE, Ianaro A, Derré L, Valerio M, Tawadros T, Jichlinski P, Nguyen-Ngoc T, Speiser DE, Verdeil G, Gestermann N, Dormond O, Kandalaft L, Coukos G, Jandus C, Ménétrier-C
J Immunother Cancer. 2019 Oct 10;7(1):257
[The new management options for lung cancer in the immunotherapy era].
Meganem H, Socianu RM, Bouchaab H, Mederos N, Nguyen-Ngoc T, Peters S, Dolcan A
Rev Med Suisse. 2019 May 15;15(651):1032-1037
Exploring personalized immunotherapy opportunities in colorectal cancer.
Navarro Rodrigo B, Bobisse S, Vigano S, Baumgartner P, Nguyen-Ngoc T, Gannon P, Genolet R, Stevenson B, Sempoux C, Sauvain M-O, Hubner M, Hahnloser D, Demartines N, Montemurro M, Kandalaft L, Rusakiewicz S, Harari A and Coukos G.
Ann Oncol 2017;28:suppl_5
Immunotherapy and targeted therapies in the treatment of non-small cell lung cancer.
Nguyen-Ngoc T, Reck M, Tan DSW and Peters S.
Eur Oncol Haematol 2017;13:35-52
Management of EGFRmut+ NSCLC with brain metastases.
Wannesson L and Nguyen-Ngoc T.
Healthbook 2017/06
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S
J Thorac Oncol. 2015 Oct;10(10):1396-403
Reinvention of chemotherapy: drug conjugates and nanoparticles.
Nguyen-Ngoc T, Raymond E
Curr Opin Oncol. 2015 May;27(3):232-42
Education et formation
FMH (oncologie médicale): 2013
Certification European Society of Medical Oncology (ESMO): 2013
PhD (biologie cellulaire): 2008
Doctorat en médecine: 2002
Institutions de formation & expériences précédentes
ISREC/EPFL
Université de Lausanne
- Hôpital de Moutier
Langues parlées
Français, Vietnamien, Anglais, Espagnol
Rue du Bugnon 46
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 0155
Rue du Bugnon 46
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 0155